NOTE: UC San Diego's institutional subscription to Pivot will be sunsetting at the end of June 2023. We strongly encourage researchers and administrators to subscribe to UC San Diego Biomedical Funding List for Limited Submission Opportunities announced by UCSD and Foundation Relations for private foundation funding opportunities. You can subscribe to other e-mails lists here.
Here is a list of internal opportunities offered by UC San Diego and the UC system.
Questions? Reach out to us at MCCGrants@health.ucsd.edu
External Grant Opportunities
Federal Sources
Source
|
Award
|
Focus Area
|
Internal Deadline
|
Sponsor Deadline
|
Award Amount/Period
|
Notes |
NIH | Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional | Improve therapeutic development in ultra-rare cancers with high unmet medical need | N/A |
LOI due date: Feb 19, 2024 Application deadline: April 5, 2024 |
$500,0000 / year, max. 3 years | |
NIH
|
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) |
Advancing and validating emerging cancer-focused technologies
|
N/A
|
April 1, 2024 Oct 1, 2024 |
$300,000 / year, max. 3 years
|
|
NIH | Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | Advancing cancer informatics technologies | N/A |
June 11, 2024 Nov 15, 2024 |
$600,000 / year, max. 5 years | |
NCI | The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional) | Transitioning mentored cancer researchers to independent faculty positions. | N/A |
June 12, 2024 Oct 12, 2024 |
$100,000 / year for salary $50,000 / year for research, cost max. 3 years | |
NIH | PAR-22-136: Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) | Training for clinician-scientists (MD, DO, PharmD, nurses with PhD) | N/A | June 17, 2024 | $50,000-Year 1, $750,000-Years 2-5 | |
NIH | Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | Research in cancer control and population sciences | N/A |
July 5, 2024 Oct 5, 2024 |
$250,000 / year / max. 5 years | |
NIH |
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) |
Potential to reduce cancer burden | N/A |
June 5, 2024 Oct 5, 2024 |
Budget not limited / max. 5 years | |
NIH | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 or U01; Clinical Trial Optional) | Incorporate a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program | N/A |
April 1, 2024 Oct 1, 2024 |
$150,000 / year / max. 2 years | |
NIH | Informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum | N/A |
Jun 11, 2024
Nov 15, 2024
|
Budget not limited / max. 5 years | ||
NIH |
Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional) |
Address challenges in cancer and cancer disparities research, education, and outreach, as well as cancer's impact on underserved populations | N/A |
Oct 9, 2024
Oct 9, 2025
|
$1.7 - 2.2 million / max. 5 years | |
NCI | Cancer-targeted diagnostic and therapeutic interventions | N/A |
June 5, 2024 Oct 5, 2024 |
$499,999 / year / max. 5 years | ||
NIH | Validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment | N/A |
June 10, 2024 Oct 8, 2024 |
$250,000 - $275,000 | ||
NIH | Support New Investigators and Early Stage Investigators (ESIs) from diverse backgrounds | N/A |
June 18, 2024 Nov 19, 2024 |
$275,000 / 2 years / max. 2 years | ||
NIH |
Advancing Genomic Medicine Research (R01 Clinical Trial Optional) |
Implement the use and sharing of genomic information and technologies in clinical care | N/A |
July 8, 2024 Feb 11, 2025 |
$500,000 / year / max. 5 years |
|
NIH | Prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers | N/A |
May 25, 2024 Sept 25, 2024 Jan 25, 2025 |
$1.4 million / per year / max. 5 years | ||
NIH |
Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) |
Support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs | N/A |
May 25, 2024
Sept 25, 2024
Jan 25, 2025
|
$300,000 / per year / 5 years |
Non-Federal Sources
Source
|
Award
|
Focus Area
|
Internal Deadline
|
Sponsor Deadline
|
Award Amount/Period
|
Notes |
Cancer-related health disparities in underserved populations
|
N/A
|
2 April 2024
|
$250,000 / 1 year
|
|||
Cancer prevention, detection, or treatment
|
N/A
|
2 April 2024
|
$250,000 / 1 year
|
|||
Collaborative cancer research
|
N/A
|
2 April 2024
|
$250,000 / 1 year
|
|||
Translational pojects for advancing to pre-clinical or clinical stages
|
N/A
|
14 May 2024
|
$500,000 / 1 year
|
|||
Innovative ground-breaking ideas intended to change the course of cancer research and care
|
N/A
|
14 May 2024
|
$1,000,000 / multiple years
|
|||
Tackle challenges in the prevention, diagnosis, and treatment of cancer
|
N/A
|
12 March 2024
|
$3,000,000 / 3 years
|
|||
Mark Foundation |
High-impact, high-risk projects
|
N/A
|
29 April 2024
|
$750,000 / 3 years
|
||
Adult cancer
|
March 8, 2024
|
April 19, 2024
|
$800,000
|
MCC Limited Submission | ||
Bristol Myers Squibb
|
Research and translation of cancer immunotherapy
|
N/A
|
April 1, 2024
|
$200,000 / 2 years
|
||
Melanoma Research Alliance
|
Research in cancer immunotherapy for the treatment of patients with melanoma
|
N/A |
April 1, 2024
|
$200,000 / 2 years
|
||
MERCK
|
Cancer immunotherapy research and translational immunotherapeutic approaches
|
N/A |
April 1, 2024
|
$100,000 / 1 year
|
||
SITC
|
Clinical or translational research in cancer immunotherapy
|
N/A |
April 1, 2024
|
$100,000 / 1 year
|
||
Mallinckrodt Pharmaceuticals
|
Research and translation of adverse events in cancer immunotherapy.
|
N/A |
April 1, 2024
|
$40,000 / 1 year
|
Internal Grant Opportunities
Award
|
Focus Area
|
Deadline
|
Award Amount/Period
|
Notes
|
---|---|---|---|---|
2024 HWSPH and MCC Pilot Project Grants | Public health and cancer control |
March 18, 2024 5 p.m. |
$15,000 - $30,000 |